Lexicon Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Lexicon Pharmaceuticals, Inc. had total assets of $185m, total liabilities of $77.4m and shareholders' equity of $108m. It held $34.3m in cash against $54.0m of debt: net debt of $19.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lexicon Pharmaceuticals, Inc.: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	101	47	186	30	37	137	203	47	62	80	36	126	64	46	22	67	34	41
Receivables	—	1	0	1	1	1	1	7	5	6	57	0	0	0	1	3	2	2
Inventory	—	—	—	—	—	—	—	0	2	5	4	0	—	0	0	0	0	1
Total current assets	—	215	286	231	135	369	532	358	322	173	338	158	89	141	177	246	102	197
Goodwill	—	45	45	45	45	45	45	45	45	45	45	45	45	45	45	45	45	45
Total assets	—	367	431	372	274	471	652	476	437	284	418	204	137	194	229	298	185	250
Accounts payable	—	3	6	8	10	13	20	53	39	12	12	5	9	10	14	15	3	2
Deferred revenue (current)	—	0	0	0	0	2	76	63	40	2	0	—	—	—	—	0	—	—
Total current liabilities	—	11	21	18	19	45	123	165	105	37	65	47	22	23	32	45	21	15
Short-term debt	—	1	1	2	2	20	2	16	14	1	11	12	0	—	—	0	5	0
Long-term debt	—	27	23	22	20	88	101	85	232	244	234	0	0	49	100	100	49	51
Total debt	0	28	25	23	22	108	106	101	252	250	249	12	1	49	100	100	54	51
Total liabilities	—	120	133	105	104	187	366	318	368	311	301	47	23	77	136	152	77	76
Shareholders' equity	163	247	298	267	170	284	286	168	68	−26	117	156	114	117	93	146	108	175
Non-controlling interests and other (assets − liabilities − equity)	—	—	—	—	—	—	—	−10	—	—	—	—	—	—	—	—	—	—
Net debt (negative = net cash)	−101	−19	−161	−7	−16	−30	−97	55	190	170	213	−114	−63	2	77	34	20	11
Shares outstanding	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	363m	366m	447m

US$ millions unless shown otherwise. Fiscal quarters.

Lexicon Pharmaceuticals, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	3	3	47	2	2	2	12	2
Inventory	1	0	0	0	0	0	0	1
Total current assets	269	246	246	145	123	102	186	197
Goodwill	45	45	45	45	45	45	45	45
Total assets	321	298	298	226	206	185	269	250
Accounts payable	14	15	11	6	4	3	3	2
Deferred revenue (current)	—	0	—	17	4	—	—	—
Total current liabilities	36	45	111	35	22	21	10	15
Short-term debt	—	0	42	—	—	5	0	0
Long-term debt	100	100	59	56	57	49	50	51
Total debt	100	100	101	56	57	54	50	51
Total liabilities	143	152	175	96	86	77	66	76
Shareholders' equity	179	146	123	129	120	108	203	175
Shares outstanding	—	363m	—	—	366m	366m	426m	447m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CUE vs LXRX LXRX vs STRO LXRX vs ZYME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lexicon Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lexicon Pharmaceuticals, Inc.